履歷(教育及工作經驗)

教育：

1. 2014-09 至 2018-06, 上海中醫藥大學, 中藥學, 學士
2. 2018-09 至 2020-08, 香港浸會大學, 生物醫學與藥物研發, 碩士
3. 2022-08 至 2025-08, 香港中文大學, 中藥學, 博士

工作經驗：

1. 2025-10 至 今, 博士後, 香港中文大學中醫學院

科研範圍

1. 核酸藥物的設計與開發；骨代謝疾病、纖維化疾病以及種瘤的研究與治療。

著作及論文（選列)

1. Shanshan Yao, Xin Yang, Meishen Ren, Huarui Zhang#, Sifan Yu, Tienan Chen, Shijian Ding, Yufei Pan, Luyao, Wang , Yuan Ma, Wei Kang, Aiping Lyu, Yixin He, Zongkang Zhang, Yuanyuan Yu, Ge Zhang & Bao-Ting Zhang. AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for Duchenne muscular dystrophy. Acta Pharm Sin B. 2026. 2026, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2026.02.016. (IF: 14.7) 
2. Ma Y, Zhang H#, Shen X, Yang X, Deng Y, Tian Y, Chen Z, Pan Y, Luo H, Zhong C, Yu S, Lu A, Zhang B, Tang T*, Zhang G*. Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy. Cancer Lett. 2024 Aug 28;598:217102. (IF: 10.1) 
3. Gubu A, Ma Y, Yu S, Zhang H#, Chen Z, Ni S, Abdullah R, Xiao H, Zhang Y, Dai H, Luo H, Yu Y, Wang L, Jiang H, Zhang N, Tian Y, Li H, Lu A, Zhang B, Zhang G. Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential. Mol Ther Nucleic Acids. 2024 Feb 13;35(1):102146. (IF: 8.8) 
4. Zhang H, Yu S, Ni S, Gubu A, Ma Y, Zhang Y, Li H, Wang Y, Wang L, Zhang Z, Yu Y, Lyu A, Zhang B, Zhang G. A bimolecular modification strategy for developing long-lasting bone anabolic aptamer. Mol Ther Nucleic Acids. 2023 Nov 10;34:102073. (IF: 8.8)
5. Liu, J., Wu, X., Lu, J., Huang, G., Dang, L., Zhang H#., Zhong, C., Zhang, Z., Li, D., Li, F., Liang, C., Yu, Y., Zhang, BT., Chen, L., Lu, A., Zhang, G. (2021). Exosomal transfer of osteoclast-derived miRNAs to chondrocytes